36.74
0.06 (0.16%)
| Previous Close | 36.68 |
| Open | 36.79 |
| Volume | 219,954 |
| Avg. Volume (3M) | 365,217 |
| Market Cap | 2,028,757,120 |
| Price / Earnings (TTM) | 34.34 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 3.15 |
| Price / Book | 2.02 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | 9.16% |
| Operating Margin (TTM) | 16.12% |
| Diluted EPS (TTM) | 1.07 |
| Quarterly Revenue Growth (YOY) | 14.20% |
| Total Debt/Equity (MRQ) | 3.79% |
| Current Ratio (MRQ) | 2.19 |
| Operating Cash Flow (TTM) | 172.50 M |
| Levered Free Cash Flow (TTM) | 162.93 M |
| Return on Assets (TTM) | 2.89% |
| Return on Equity (TTM) | 6.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Supernus Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 2.0 |
| Average | -0.88 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 5.01% |
| % Held by Institutions | 113.26% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KHATTAR JACK A. | - | 37.18 | -25,233 | -938,163 |
| RUBIN JONATHAN | - | 37.18 | -1,102 | -40,972 |
| Aggregate Net Quantity | -26,335 | |||
| Aggregate Net Value ($) | -979,135 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 37.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KHATTAR JACK A. | Officer | 27 Dec 2024 | Disposed (-) | 25,233 | 37.18 | 938,163 |
| KHATTAR JACK A. | Officer | 27 Dec 2024 | Option execute | 52,640 | - | - |
| RUBIN JONATHAN | Officer | 27 Dec 2024 | Disposed (-) | 1,102 | 37.18 | 40,972 |
| RUBIN JONATHAN | Officer | 27 Dec 2024 | Option execute | 2,625 | - | - |
| Date | Type | Details |
|---|---|---|
| 26 Nov 2024 | Announcement | Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference |
| 13 Nov 2024 | Announcement | Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference |
| 04 Nov 2024 | Announcement | Supernus Announces Third Quarter 2024 Financial Results |
| 31 Oct 2024 | Announcement | Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 |
| 21 Oct 2024 | Announcement | Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results |
| 17 Oct 2024 | Announcement | Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder |
| 10 Oct 2024 | Announcement | Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |